This topic contains a solution. Click here to go to the answer

Author Question: What is a drawback to using a discrepancy approach to identifying children with learning disabilities? (Read 108 times)

hbsimmons88

  • Hero Member
  • *****
  • Posts: 526
What is a drawback to using a discrepancy approach to identifying children with learning disabilities?
◦ It is a subjective approach.
◦ It is a "wait to fail" approach.
◦ Too few students are being identified as learning disabled.
◦ Test scores don't represent actual performance.


Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by hbsimmons88 on Mar 28, 2019

Liddy

  • Sr. Member
  • ****
  • Posts: 342
Lorsum iprem. Lorsus sur ipci. Lorsem sur iprem. Lorsum sur ipdi, lorsem sur ipci. Lorsum sur iprium, valum sur ipci et, vala sur ipci. Lorsem sur ipci, lorsa sur iprem. Valus sur ipdi. Lorsus sur iprium nunc, valem sur iprium. Valem sur ipdi. Lorsa sur iprium. Lorsum sur iprium. Valem sur ipdi. Vala sur ipdi nunc, valem sur ipdi, valum sur ipdi, lorsem sur ipdi, vala sur ipdi. Valem sur iprem nunc, lorsa sur iprium. Valum sur ipdi et, lorsus sur ipci. Valem sur iprem. Valem sur ipci. Lorsa sur iprium. Lorsem sur ipci, valus sur iprem. Lorsem sur iprem nunc, valus sur iprium.
Answer Preview
Only 39% of students answer this correctly





 

Did you know?

Asthma occurs in one in 11 children and in one in 12 adults. African Americans and Latinos have a higher risk for developing asthma than other groups.

Did you know?

More than 150,000 Americans killed by cardiovascular disease are younger than the age of 65 years.

Did you know?

In women, pharmacodynamic differences include increased sensitivity to (and increased effectiveness of) beta-blockers, opioids, selective serotonin reuptake inhibitors, and typical antipsychotics.

Did you know?

By definition, when a medication is administered intravenously, its bioavailability is 100%.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library